Scientific Resources Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity (Poster presented at SITC 2025) 2.5 MB Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity (Poster presented at SITC 2025) 1.5 MB Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation (Poster presented at SITC 2025) 2.4 MB Development of WTX-921, A Conditionally Active IL-10 INDUKINE™ Molecule for the Treatment of Inflammatory Bowel Disease (Poster presented at AAI 2025) 2.8 MB INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in a Murine Syngeneic Tumor Model (Poster presented at SITC 2024) 8.5 MB The Tumor-Activated IL-12 Prodrug WTX-330 Expanded and Activated Tumor Infiltrating Lymphocytes and Caused Tumor Regression in Patients with Refractory Solid Tumors: Interim Data From an Ongoing Phase 1 Study (Poster presented at SITC 2024) 6 MB A phase 1/1b trial of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy (Poster presented at ASCO 2024) 3.8 MB Development of Conditionally Active IL-10 INDUKINE™ Molecules for the Treatment of Inflammatory Bowel Disease (Poster presented at AAI 2024) 1.9 MB Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (Poster presented at AACR 2024) 2.6 MB WTX-712, a conditionally active IL-21 INDUKINE™ molecule, induces a strong anti-tumor phenotype through a differentiated mechanism (Poster presented at AACR 2024) 3 MB Current page 1 Page 2 Page 3 Next page › Last page »
Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity (Poster presented at SITC 2025) 2.5 MB
Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity (Poster presented at SITC 2025) 1.5 MB
Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation (Poster presented at SITC 2025) 2.4 MB
Development of WTX-921, A Conditionally Active IL-10 INDUKINE™ Molecule for the Treatment of Inflammatory Bowel Disease (Poster presented at AAI 2025) 2.8 MB
INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in a Murine Syngeneic Tumor Model (Poster presented at SITC 2024) 8.5 MB
The Tumor-Activated IL-12 Prodrug WTX-330 Expanded and Activated Tumor Infiltrating Lymphocytes and Caused Tumor Regression in Patients with Refractory Solid Tumors: Interim Data From an Ongoing Phase 1 Study (Poster presented at SITC 2024) 6 MB
A phase 1/1b trial of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy (Poster presented at ASCO 2024) 3.8 MB
Development of Conditionally Active IL-10 INDUKINE™ Molecules for the Treatment of Inflammatory Bowel Disease (Poster presented at AAI 2024) 1.9 MB
Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (Poster presented at AACR 2024) 2.6 MB
WTX-712, a conditionally active IL-21 INDUKINE™ molecule, induces a strong anti-tumor phenotype through a differentiated mechanism (Poster presented at AACR 2024) 3 MB
